Dr. Liu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-5269Fax+1 617-632-3479- Is this information wrong?
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2005 - 2008
- Brigham and Women's HospitalResidency, Internal Medicine, 2002 - 2005
- Harvard Medical SchoolClass of 2002
Certifications & Licensure
- FL State Medical License 2022 - Present
- MA State Medical License 2004 - 2025
- VT State Medical License 2023 - 2024
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Start of enrollment: 2010 Apr 14
- A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer Start of enrollment: 2011 Apr 01
- A Study of BBI503 in Adult Patients With Advanced Solid Tumors Start of enrollment: 2012 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors.Ryan B Corcoran, Khanh T Do, Jeong E Kim, James M Cleary, Aparna R Parikh, Oladapo O Yeku, Niya Xiong, Colin D Weekes, Jennifer Veneris, Leanne G Ahronian, Gianluca Ma...> ;Clinical Cancer Research. 2024 May 1
- Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancer.Xiong, N., Sawyer, H., Polak, M., Needham, H., Geddes, M., Koppermann, L., Shea, M., Castro, C., Cheng, S., Konstantinopoulos, P., Krasner, C., Liu, J., Matulonis, U.,...> ;Gynecologic Oncology Reports. 2024 Apr 1
- Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses.Panagiotis A Konstantinopoulos, Su-Chun Cheng, Elizabeth K Lee, Alexandre André B A da Costa, Doga Gulhan, Andrea E Wahner Hendrickson, Bose Kochupurakkal, David L Kol...> ;JCO Precision Oncology. 2024 Apr 1
- Join now to see all
Press Mentions
- Nivolumab/bevacizumab Combo Promising in Relapsed Ovarian CancerOctober 19th, 2019
- OncLive® Presents Latest State of the Science Summit™ on Ovarian Cancer and STSNovember 29th, 2018
- Update Sustains Olaparib/Cediranib PFS Benefit in Ovarian CancerJune 9th, 2017
- Join now to see all
Hospital Affiliations
- Dana-Farber Cancer InstituteBoston, Massachusetts
- Boston Children's HospitalBoston, Massachusetts
- Brigham and Women's HospitalBoston, Massachusetts
- Salem HospitalSalem, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: